Medway School of Pharmacy
The Research Excellence Framework also assesses the impact that the research has outside academia. The case studies below are a selection of the research submitted by Medway School of Pharmacy.
Guide for pharmacologists
Professor Alistair Mathie
The proliferation of drug targets in recent years created the need for a new research resource. Kent researcher Alistair Mathie was one of three contributors who produced the authoritative but user-friendly Guide to Receptors and Channels (GRAC).
In writing the guide, opinions were sought from consultants and experts across the field in order to provide an authoritative consensus. There was also an emphasis on ease of use, so a newcomer to a particular target group could identify the main elements at a glance.
As an academic resource, GRAC receives numerous citations and influences the education of students around the world. It is also having a substantial impact on research in industry. In recognition of its importance, Mathie and his colleagues were awarded the Rang Prize from the British Pharmacological Society.
Dr Claire Peppiatt-Wildman, Dr Scott Wildman
Through the visualisation of cellular events in live tissue, researchers Claire Peppiatt-Wildman and Scott Wildman have developed new models for investigating kidney and bladder function in states of health and disease. Their findings represent a significant step forward, helping clinicians and physiologists to understand responses to drug-toxicity, and the onset and progression of disease.
The imaging of live bladder tissue, adapted for bedside application, has already altered clinical practice within the NHS. And the technology could help to develop new drugs to treat kidney disease. The research team has established collaborative links with the pharmaceutical company Pfizer and biotechnology company Biogen Idec.
Nanoparticles in drug delivery
Dr Vadim Sumbayev
Research in the emerging area of nanotechnology, has shown that gold nanoparticles may be the key to developing new treatments for diseases such as allergy, leukaemia and autoimmune disorders.
Nanoparticles are so small that they operate on the same scale as biologically active macromolecules, and gold nanoparticles were found to be an excellent platform for drug delivery. With clear potential for therapeutic innovation, these findings led to Vadim Sumbayev’s collaboration with the Institute for Health and Consumer Protection (part of the European Commission Joint Research Centre). The work has inspired further research from companies who specialise in nanotechnology, nanobiotechnology and synthetic biology.